ANIX vs ANTX

Anixa Biosciences, Inc. vs AN2 Therapeutics, Inc. — Valuation Comparison 2026

ANIX

Biotechnology
Anixa Biosciences, Inc.
Quality
4.4
out of 10
Value Trap
12
SAFE
Price
$2.70
Last close
Models
7/13
Active
VS

ANTX

Biotechnology
AN2 Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
18
SAFE
Price
$4.46
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ANIX Fair ValueANIX Upside ANTX Fair ValueANTX Upside
Bayesian DCF Intrinsic $0.76 -71.7% $2.01 -55.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.04 -98.7% $0.38 -91.4%
Dynamic NAV Asset-Based $0.79 -70.7% $2.77 -38.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANIX vs ANTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANIX vs ANTX — Which Stock Is More Undervalued?

ANIX scores higher with a 4.4/10 quality rating vs ANTX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Anixa Biosciences, Inc. (ANIX) and AN2 Therapeutics, Inc. (ANTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANIX currently trades at $2.70 with a QOC of 4.4/10, while ANTX trades at $4.46 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).